US009409917B2

(12) **United States Patent**
Hilpert et al.

(10) **Patent No.: US 9,409,917 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS**

(71) Applicants: **Kurt Hilpert**, Hofstetten (CH); **Francis Hubler**, Hegenheim (FR); **Thierry Kimmerlin**, Riehen (CH); **Dorte Renneberg**, Basel (CH); **Simon Stamm**, Allschwil (CH)

(72) Inventors: **Kurt Hilpert**, Hofstetten (CH); **Francis Hubler**, Hegenheim (FR); **Thierry Kimmerlin**, Riehen (CH); **Dorte Renneberg**, Basel (CH); **Simon Stamm**, Allschwil (CH)

(73) Assignee: **ACTELION PHARMACEUTICALS LTD.**, Allschwil (CH)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/373,338**

(22) PCT Filed: **Jan. 18, 2013**

(86) PCT No.: **PCT/IB2013/050479**

§ 371 (c)(1),
(2) Date: **Jul. 18, 2014**

(87) PCT Pub. No.: **WO2013/108227**

PCT Pub. Date: **Jul. 25, 2013**

(65) **Prior Publication Data**

US 2015/0025075 A1 Jan. 22, 2015

(30) **Foreign Application Priority Data**

Jan. 20, 2012 (WO) PCT/IB2012/050282

(51) **Int. Cl.**
C07D 491/048 (2006.01)

(52) **U.S. Cl.**
CPC ***C07D 491/048*** (2013.01)

(58) **Field of Classification Search**
CPC C07D 491/048
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2007/0281939	A1	12/2007	Dombrowski et al.
2012/0157494	A1	6/2012	Harris, III et al.
2014/0073651	A1	3/2014	Hilpert et al.
2014/0163035	A1	6/2014	Hilpert et al.

FOREIGN PATENT DOCUMENTS

EP	2 243 772	A1	10/2010
WO	WO 00/61569		10/2000
WO	WO 01/42194	A1	6/2001
WO	WO 01/44170	A1	6/2001
WO	WO 01/94338	A1	12/2001
WO	WO 03/041707	A1	5/2003
WO	WO 03/042190	A1	5/2003
WO	WO 03/042191	A1	5/2003
WO	WO 03/080579	A1	10/2003
WO	WO 2004/058270	A1	7/2004
WO	WO 2004/058731	A1	7/2004
WO	WO 2004/074224	A1	9/2004
WO	WO 2004/106305	A1	9/2004
WO	WO 2004/099146	A1	11/2004
WO	WO 2005/009968	A1	2/2005
WO	WO 2005/111003	A1	11/2005
WO	WO 2006/025783	A1	3/2006
WO	WO 2006/059945	A1	6/2006
WO	WO 2006/080884	A1	8/2006
WO	WO 2006/102610	A2	9/2006
WO	WO 2007055374	A1 *	5/2007
WO	WO 2007/109154	A2	9/2007
WO	WO 2007/109160	A2	9/2007
WO	WO 2007/109172	A2	9/2007
WO	WO 2007/109182	A2	9/2007
WO	WO 2007/109192	A2	9/2007
WO	WO 2007/109201	A2	9/2007
WO	WO 2007/141267	A1	12/2007
WO	WO 2007/141269	A1	12/2007
WO	WO 2008/003697	A1	1/2008
WO	WO 2008/066789	A2	6/2008
WO	WO 2008/094473	A1	8/2008
WO	WO 2008/112205	A1	9/2008
WO	WO 2008/114002	A1	9/2008
WO	WO 2008/116814	A1	10/2008
WO	WO 2008/116845	A1	10/2008
WO	WO 2008/119685	A2	10/2008
WO	WO 2008/119825	A2	10/2008
WO	WO 2008/124153	A1	10/2008
WO	WO 2008/125600	A2	10/2008

(Continued)

OTHER PUBLICATIONS

Stock "Efficacy and Safety of CE-224,535, an Antagonist of P2X7 Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate" The Journal of Rheumatology 2012; 39:4; 720-727.*

Damia "Contemporary pre-clinical development of anticancer agents—What are the optimal preclinical models?" European Journal of Cancer 2009, 45, 2768-2781.*

Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, 1996 vol. 1, pp. 1004-1010.*

Sharma "Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents" Nature Reviews Cancer Apr. 2010, vol. 10, 241-253.*

(Continued)

Primary Examiner — David K. O'Dell

(74) *Attorney, Agent, or Firm* — Hoxie & Associates LLC

(57) **ABSTRACT**

The invention relates to heterocyclic amide derivatives of formula (I),

(I)



wherein R^1, R^2, R^3, X and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

16 Claims, No Drawings